MeSH term
Frequency | Condition_Probility | Binding Sites | 3 | 0.0 |
Humans | 200 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Mutation | 14 | 0.0 |
Adult | 79 | 0.0 |
English Abstract | 35 | 0.0 |
Female | 113 | 0.0 |
Pedigree | 36 | 0.0 |
Phenotype | 24 | 0.0 |
beta-Thalassemia/*genetics | 16 | 69.0 |
Comparative Study | 25 | 0.0 |
Greece | 5 | 5.0 |
*Heterozygote | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 65 | 0.0 |
Adolescent | 45 | 0.0 |
Child | 51 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Male | 100 | 0.0 |
Sex Factors | 3 | 0.0 |
Aged | 20 | 0.0 |
Blood Viscosity | 2 | 5.0 |
Middle Aged | 47 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Osmotic Fragility | 2 | 16.0 |
Turkey/epidemiology | 4 | 5.0 |
beta-Thalassemia/diagnosis/*epidemiology/genetics | 2 | 100.0 |
Base Sequence | 26 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Hemoglobins, Abnormal/*analysis/genetics | 2 | 28.0 |
Pregnancy | 11 | 0.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Bone Marrow/pathology | 2 | 0.0 |
Child, Preschool | 35 | 0.0 |
Genotype | 11 | 0.0 |
Heterozygote | 37 | 1.0 |
Infant | 19 | 0.0 |
Globins/*genetics | 28 | 23.0 |
Hemoglobin A2/*metabolism | 6 | 85.0 |
Point Mutation | 3 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Animals | 5 | 0.0 |
Base Composition | 2 | 0.0 |
Mice | 3 | 0.0 |
Syndrome | 3 | 0.0 |
Reference Standards | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Reproducibility of Results | 6 | 0.0 |
Thalassemia/diagnosis | 5 | 83.0 |
Haplotypes/genetics | 4 | 0.0 |
Hemoglobin A2/genetics | 3 | 100.0 |
Molecular Sequence Data | 21 | 0.0 |
RNA Splicing | 2 | 0.0 |
beta-Thalassemia/blood/*genetics | 3 | 75.0 |
Follow-Up Studies | 2 | 0.0 |
Genetic Counseling | 2 | 1.0 |
Hemoglobin E/*genetics | 2 | 40.0 |
Infant, Newborn | 9 | 0.0 |
Erythrocytes/chemistry | 3 | 6.0 |
Globins/genetics | 15 | 13.0 |
Mutation/*genetics | 5 | 0.0 |
*Point Mutation | 8 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Erythrocyte Indices | 16 | 25.0 |
Fetal Hemoglobin/analysis | 21 | 60.0 |
*Gene Deletion | 2 | 0.0 |
Hemoglobin A2/analysis | 25 | 96.0 |
Thailand | 3 | 2.0 |
Hemoglobin A2/*analysis | 23 | 100.0 |
beta-Thalassemia/*diagnosis | 3 | 100.0 |
Alleles | 3 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
alpha-Thalassemia/*genetics | 3 | 21.0 |
Analysis of Variance | 2 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Malaria/*epidemiology | 2 | 22.0 |
Prevalence | 7 | 0.0 |
Reference Values | 5 | 0.0 |
Risk Factors | 2 | 0.0 |
Haplotypes | 5 | 0.0 |
Hematocrit | 10 | 2.0 |
Electrophoresis, Cellulose Acetate | 4 | 10.0 |
Case-Control Studies | 3 | 0.0 |
Hemoglobin A2/*genetics | 7 | 100.0 |
India | 4 | 1.0 |
beta-Thalassemia/blood/diagnosis/*genetics | 2 | 100.0 |
Mass Screening/*methods | 3 | 5.0 |
Sensitivity and Specificity | 2 | 0.0 |
DNA/analysis | 5 | 0.0 |
Fetal Hemoglobin/*analysis | 8 | 50.0 |
Gene Deletion | 2 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Homozygote | 14 | 0.0 |
Mass Screening | 2 | 1.0 |
Anemia, Sickle Cell/*blood | 6 | 19.0 |
Prospective Studies | 2 | 0.0 |
Electrophoresis, Capillary/*methods | 2 | 6.0 |
Evaluation Studies | 3 | 0.0 |
Hemoglobins/*analysis/classification | 2 | 100.0 |
Codon/*genetics | 2 | 3.0 |
Gene Amplification | 2 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Cell Line | 3 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Transfection | 2 | 0.0 |
Incidence | 4 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
False Negative Reactions | 2 | 1.0 |
Hemoglobin A, Glycosylated/*analysis | 4 | 1.0 |
Hemoglobins, Abnormal/*analysis | 4 | 20.0 |
*Erythrocyte Aging | 2 | 9.0 |
Hemoglobin A/analysis | 4 | 11.0 |
Hemoglobins/*analysis | 6 | 11.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Heterozygote Detection | 11 | 2.0 |
*Mutation | 6 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Thalassemia/*genetics | 11 | 52.0 |
Hemoglobins, Abnormal/*genetics | 2 | 10.0 |
Hemoglobin, Sickle/analysis | 3 | 30.0 |
Isoelectric Focusing/*methods | 2 | 5.0 |
beta-Thalassemia/*blood | 4 | 36.0 |
Thalassemia/blood/*epidemiology/genetics | 2 | 100.0 |
DNA/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Chromosome Mapping | 10 | 0.0 |
Iron/deficiency | 2 | 15.0 |
*Homozygote | 2 | 1.0 |
Time Factors | 4 | 0.0 |
Hemoglobins, Abnormal/analysis | 4 | 36.0 |
Thalassemia/blood/diagnosis | 3 | 100.0 |
Codon | 3 | 0.0 |
Chromatography | 2 | 1.0 |
Age Factors | 8 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Ethnic Groups | 4 | 1.0 |
Hemoglobin, Sickle/*analysis | 2 | 50.0 |
Statistics, Nonparametric | 2 | 0.0 |
*Chromatography, High Pressure Liquid | 2 | 16.0 |
Diagnosis, Differential | 6 | 0.0 |
Protoporphyrins/*blood | 2 | 16.0 |
Fetal Hemoglobin/metabolism | 5 | 83.0 |
Hemoglobin A2/metabolism | 3 | 100.0 |
Italy | 7 | 1.0 |
DNA/genetics | 5 | 0.0 |
Introns | 2 | 0.0 |
Japan | 2 | 0.0 |
RNA Splicing/genetics | 2 | 1.0 |
Hemoglobins/analysis | 9 | 3.0 |
Thalassemia/*blood | 3 | 42.0 |
Fetal Hemoglobin/*physiology | 2 | 100.0 |
Hemoglobin A2/*physiology | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
DNA Restriction Enzymes/metabolism | 3 | 3.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Hemoglobins/*analysis/genetics | 2 | 100.0 |
Variation (Genetics) | 5 | 0.0 |
Hemoglobinopathies/*genetics | 2 | 33.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Hemoglobins/*biosynthesis | 3 | 60.0 |
*Chromosome Deletion | 4 | 0.0 |
Thalassemia/blood/*genetics | 9 | 90.0 |
Chromosome Deletion | 5 | 0.0 |
Thalassemia/blood/*complications/genetics | 2 | 66.0 |
Karyotyping | 2 | 0.0 |
Thalassemia/complications/*genetics | 2 | 50.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Hemoglobins/*genetics | 2 | 12.0 |
Isoelectric Focusing | 5 | 0.0 |
Thalassemia/blood/epidemiology/*genetics | 2 | 100.0 |
Saudi Arabia | 2 | 4.0 |
Erythrocyte Count | 8 | 8.0 |
Splenomegaly/etiology | 2 | 11.0 |
*Erythrocyte Indices | 4 | 30.0 |
Thalassemia/*blood/genetics | 10 | 90.0 |
Immunoblotting | 2 | 0.0 |
Anemia, Sickle Cell/blood/*complications | 2 | 50.0 |
Sickle Cell Trait/epidemiology | 3 | 100.0 |
Thalassemia/epidemiology | 2 | 50.0 |
Liberia | 3 | 75.0 |
Thalassemia/*diagnosis | 3 | 100.0 |
Fetal Hemoglobin/*analysis/genetics | 2 | 100.0 |
Blood Cell Count | 5 | 2.0 |
Down Syndrome/*blood | 2 | 18.0 |
Iron/blood | 4 | 4.0 |
Prognosis | 2 | 0.0 |
Blood Protein Electrophoresis | 4 | 3.0 |
Hemoglobin A/*analysis | 14 | 30.0 |
Cloning, Molecular | 2 | 0.0 |
Fetal Hemoglobin/*biosynthesis | 3 | 37.0 |
Hemoglobin A/*biosynthesis | 4 | 80.0 |
Hemoglobin A2/*biosynthesis | 2 | 100.0 |
Hemoglobin A/*genetics | 2 | 100.0 |
*Chromatography | 2 | 25.0 |
Bilirubin/blood | 2 | 2.0 |
Thalassemia/complications | 2 | 66.0 |
Hemoglobin A/genetics | 2 | 33.0 |
Gestational Age | 2 | 0.0 |
Ferritin/blood | 4 | 2.0 |
Globins/biosynthesis | 5 | 33.0 |
Methods | 3 | 1.0 |
Hemoglobin A/*metabolism | 2 | 13.0 |
Erythrocyte Volume | 2 | 10.0 |
Jamaica | 4 | 18.0 |
Isoelectric Focusing/methods | 2 | 6.0 |
Mathematics | 2 | 1.0 |
False Positive Reactions | 2 | 0.0 |
Anemia/*blood | 2 | 13.0 |
Genes, Structural | 2 | 0.0 |
Amino Acids/analysis | 2 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Thalassemia/blood | 2 | 28.0 |
Thalassemia/*blood/complications | 2 | 50.0 |
Germany, West | 2 | 4.0 |
Anemia, Hypochromic/*diagnosis | 2 | 100.0 |
I Blood-Group System | 2 | 50.0 |
Sickle Cell Trait/diagnosis | 2 | 100.0 |
Electrophoresis, Starch Gel | 2 | 1.0 |
Iron/*blood | 2 | 5.0 |
Hemolysis | 2 | 0.0 |
Hemoglobinometry | 3 | 9.0 |
